Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat

Life Sciences

Volumn 73, Issue 18, 2003, Pages 2345-2353

  Helyes, Zsuzsanna ^a   Németh, József ^b   Thán, Márta ^a   Bölcskei, Kata ^a   Pintér, Erika ^a   Szolcsányi, János ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Anandamide; Calcitonin gene related peptide; Capsaicin sensitive nerve terminals; Neuropathic hyperalgesia; Palmitylethanolamide; Radioimmunoassay; Resiniferatoxin; Somatostatin; SR141716A; SR144528

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; NEUROPEPTIDE; PALMIDROL; RESINIFERATOXIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERALGESIA; MALE; NERVE LIGATION; NOCICEPTIVE RECEPTOR; NONHUMAN; PAIN THRESHOLD; RAT; SCIATIC NERVE;

PISUM SATIVUM;

EID: 0041570182     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00651-9     Document Type: Article

References (31)

1. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by cannabinoids. Nature. 396:1998;277-281.
2. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of endogenous fatty acid amide, palmitylethanolamide. European Journal of Pharmacology. 419:2001;191-198.
3. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:1997;816-824.
4. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
5. Fukuoka T., Tokunaga A., Kondo E., Miki K., Tachibana T., Noguchi K. Change in mRNAs for neuropeptides and the GABA (A) receptor in dorsal root ganglion neurons in a rat experimental neuropathic pain model. Pain. 78:1998;13-26.
6. Hökfelt T., Zhang X., Wiesenfeld-Hallin Zs. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends in Neuroscience. 17:1994;22-30.
7. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S.C. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
8. Lambert D.M., DiPaolo F.G., Sonveaux P., Kanyonyo M., Govaerts S.J., Hermans E., Bueb J., Delzenne N.M., Tschirhart E.J. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochemical and Biophysical Acta. 1440:1999;266-274.
9. Malan T.P., Ibrahim M.M., Lai J., Vanderah T.W., Makriyan A., Porreca F. CB(2) cannabinoid receptor agonists: pain relief without psychoactive effects? Current Opinion in Pharmacology. 3(1):2003;62-67.
10. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadec anandamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. European Journal of Pharmacology. 300:1996;227-236.
11. Németh J., Helyes Zs., Görcs T., Gardi J., Pintér E., Szolcsányi J. Development of somatostatin radioimmunoassay for the measurement of plasma and tissue contents of hormone. Acta Physiologica Hungarica. 84:1996;313-315.
12. Németh J., Görcs T., Helyes Z., Oroszi G., Kocsy T., Pintér E., Szolcsányi J. Development of a new sensitive CGRP radioimmunoassay for neuropharmacological research. Neurobiology. 6:1998;473-475.
13. 125I-labeling and purification of peptide hormones and bovine serum albumin. Journal of Radioanalytical and Nuclear Chemistry. 251:2002;129-133.
14. Németh J., Helyes Zs., Thán M., Jakab B., Pintér E., Szolcsányi J. Concentraction-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae. Neuroscience Letters. 336:2003;89-92.
15. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics. 74:1997;129-180.
16. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998;111-119.
17. Richardson J.D., Aanonsen L., Hargreaves K.M. Anti-hyperalgesic effect of spinal cannabinoids. European Journal of Pharmacology. 345:1998;145-153.
18. Rittenhouse P.A., Marchand J.E., Chen J., Kream R.M., Leeman S.E. Streptozotocin-induced diabetes is associated with altered expression of peptide-encoding mRNAs in rat sensory neurons. Peptides. 17:1996;1017-1022.
19. Seltzer Z., Dubner R., Shir Y. A novel behavioral model of neuropathic pain disorders, produced in rats by partial sciatic nerve injury. Pain. 43:1990;205-218.
20. Siegling A., Hofmann H.A., Denzer D., Mauler F., De Vry J. Cannabinoid CB1 receptor upregulation in a rat chronic neuropathic pain. European Journal of Pharmacology. 415(1):2001;R5-R7.
21. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. Journal of Pharmacology and Experimental Therapeutics. 278:1996;989-999.
22. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). British Journal of Pharmacology. 129:2000;227-230.
23. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacology Biochemistry and Behavior. 60:1998;183-191.
24. Stanton-Hicks M., Salamon J. Stimulation of the central and peripheral nervous system for the control of pain. Journal of Clinical Neurophysiology. 14:1997;46-62.
25. Szállási A., Blumberg P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacological Reviews. 51:1999;159-211.
26. Szolcsányi J. Anandamide and the question of its functional role for activation of capsaicin receptors. Trends in Pharmacological Science. 21:2000;203-204.
27. Szolcsányi J. Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends in Pharmacological Science. 21:2000;41-42.
28. Szolcsányi J., Pintér E., Helyes Z., Oroszi G., Németh J. Sytemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. British Journal of Pharmacology. 125:1998;916-922.
29. Szoke É., Balla Z., Csernoch L., Czéh G., Szolcsányi J. Interacting effects of capsaicin and anandamide on intracellular calcium in sensory neurons. Neuroreport. 11:2000;1949-1952.
30. Vaughan C.W., Connor M., Bagley E.E., Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurones in vitro. Molecular Pharmacology. 57:2000;288-295.
31. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., DiMarzo V., Julius D., Högestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-456.